Logo for BridgeBio Pharma Inc

BridgeBio Pharma Investor Relations Material

Latest events

Logo for BridgeBio Pharma

Q4 2023

22 Feb, 2024
Logo for BridgeBio Pharma

Investor Presentation

5 Dec, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Segment Data
Access more data
Revenue by
License and services revenue
Product sales
Expenses by
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company's lead candidates for the treatment of Fabry disease comprise a pipeline of recombinant enzyme-replacement therapies comprising elaprase and lysosomal-phospholipid-glycoprotein (PLG) analogs. It focuses on developing therapeutics for treating Fabry disease, a rare genetic disorder characterized by progressive loss of kidney function and the buildup of fatty substances that damage blood vessels and organs. BridgeBio Pharma, Inc.i s based in Waltham, Massachusetts.